Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new ...

Flagship Pioneering -founded Valo Health has announced the appointment of Dr Brian Alexander as its new CEO. Additionally, ...

The US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics’ KEBILIDI, the first gene ...

In Shanghai, more than 300 industry leaders, experts, and partners met to discuss the latest trends in the data centre ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...